Clinical Trial Update: Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating dalcetrapib versus placebo in a genetically defined population with recent acute coronary syndrome; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Dalcetrapib (dalcetrapib)

Snippet

Sponsor: DalCor Pharmaceuticals | Conditions: Acute Coronary Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2022-10-12